Wild-type (senile) amyloidosis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Wild-type (senile) amyloidosis}}
{{Wild-type (senile) amyloidosis}}
{{CMG}}
{{CMG}}{{AE}}{{Sab}}


==Overview==
==Overview==

Revision as of 17:59, 17 December 2019

Wild-type (senile) amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Wild-type (senile) amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wild-type (senile) amyloidosis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wild-type (senile) amyloidosis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wild-type (senile) amyloidosis epidemiology and demographics

CDC on Wild-type (senile) amyloidosis epidemiology and demographics

Wild-type (senile) amyloidosis epidemiology and demographics in the news

Blogs on Wild-type (senile) amyloidosis epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Wild-type (senile) amyloidosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide. The actual incidence of wild-type (senile) amyloidosis in particular is unknown. he mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries. Patients with wild-type (senile) amyloidosis are almost always elderly (65 years of age or older). There is no racial predilection to wild-type (senile) amyloidosis. Men are traditionally more commonly affected by wild-type (senile) amyloidosis than women.

Epidemiology and Demographics

Incidence

  • The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.[1]
  • The actual incidence of wild-type (senile) amyloidosis in particular is unknown.

Prevalence

  • The prevalence of wild-type (senile) amyloidosis has not been determined.

Mortality rate

  • The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.[2]

Age

  • Patients with wild-type (senile) amyloidosis are almost always elderly (65 years of age or older).

Race

  • There is no racial predilection to wild-type (senile) amyloidosis.

Gender

  • Men are traditionally more commonly affected by wild-type (senile) amyloidosis than women.

References

  1. Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
  2. Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.